Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CCB International To Set Up First Health Care Industry Fund With RMB 5 Billion

This article was originally published in PharmAsia News

Executive Summary

CCB International, a wholly-owned subsidiary of China Construction Bank Corporation, recently revealed that it has been establishing a health care investment fund since November 2007. With a first phase investment not exceeding RMB 5 billion, the Tianjin-registered fund will be China's first private equity focusing on the health care industry, including pharmaceuticals, medical devices, medical institutions and health care services. The seven-year closed-end fund obtains capital from various undisclosed sources. CCB International will collaborate with well-known domestic and overseas health care management funds and groups to jointly manage the fund. According to survey, China has a total of 5,744 health care management organizations covering 23 provinces, four municipalities and four autonomous regions. (Click here for more - Chinese Language)

You may also be interested in...

QUOTED. 22 October. Robert Ford.

Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.

China Regulatory Express: Biosecurity Law, Export Controls And The Life Science Sector

With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.

Mediocre Vaccine Could Make Pandemic Worse, Non-Profit Group Tells US FDA

Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts